The global market for the pharmaceutical sector experienced an increasing trend in the price of the Oxcarbazepine Active Pharmaceutical Ingredient for the last month of 2025, and it is expected to continue in January 2026. The trend is contrary to what was experienced in the pharmaceutical sector in the middle of 2025, which was driven by the tightening of supply chains, rising production costs, and global trade trends. The export price for the main exporting countries of India and China has been increasing due to prudent selling, along with rising downstream oxcarbazepine demands for the last month of the year. Rising costs in terms of feed stock, solvents, and energy have made it imperative for the sector to revise their pricing strategies in order to maintain their profit margins. On the other hand, in terms of imports, buyers across the global market are now facing higher landing costs owing to freight inflation, upstream material dependencies, specifically in China, and minimum import prices. Forecasts indicate that oxcarbazepine prices are likely to remain under pressure in the first quarter of 2026 owing to rising demand for neurological formulations.
